ClinicalTrials.gg
Active, not recruitingNCT07571915Updated Oct 8, 2026

Health-Related Quality of Life and Metabolic Outcomes in PCOS

An interventional study of Intervention Group in PCOS (Polycystic Ovary Syndrome), sponsored by The Cleveland Clinic. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Prevention

How we know

Updated Oct 8, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 183 studies in Polycystic Ovary Syndrome with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Polycystic Ovary Syndrome · United States.

Planned enrollment
66th of 146
40 · median 39
Started
2026
with 5 others
No phase
74 of 183
12 open now
Primary completion
2027-05
later than 28 of 41 live
Registered
179th of 183
by date

Among the 183 studies in Polycystic Ovary Syndrome with a site in United States, this one is the 66th largest by planned enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2026, is one of 74 with no phase, reaches primary completion later than 28 of the 41 other live ones, and was the 179th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

32 of the 183 studies in Polycystic Ovary Syndrome with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 49 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Polycystic Ovary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary outcome of interest is change in PCOS health-related quality of life, while the secondary outcome of interest is change in adiposity, cardiometabolic, and inflammation biomarkers.

Read the detailed description

The proposed feasibility study seeks to test a short-term intervention focused on comprehensive PCOS (Polycystic Ovarian Syndrome) education and lifestyle modification support. The intervention, which will utilize an evidence-based PCOS curriculum, will be implemented by a multidisciplinary team of health providers via synchronous virtual group format.

03

Conditions studied

  • PCOS (Polycystic Ovary Syndrome)
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-pregnant females ages 18-49 years
  2. Preexisting diagnoses of PCOS and obesity (body-mass index () equal or greater to 30 kg/m2) at enrollment

Exclusion criteria

Exclusion Criteria:

  1. Patients who are pregnant or planning to become pregnant during the study period
  2. Patients currently or with recent participation (\< 12 months at the time of enrollment) in a PCOS-focused group
  3. Patients with documented monogenic obesity
  4. Patients with a diagnosis of any type of diabetes (with the exclusion of prediabetes)
  5. Patients on systemic therapy > 7 days at the time of enrollment
  6. Patients with any end-stage organ disease
  7. Patients without access to internet
  8. Patients requiring English language interpretation
  9. Any condition which, based on the investigator's medical judgment, would preclude patient ability to complete the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Participants will complete seca mBCA (medical Body Composition Analyzer), lab workup, and questionaries

  • Experimental
    Intervention Group

    Participants will complete a seca mBCA (medical Body Composition Analyzer), lab workup, and questionaries Short term comprehensive PCOS education coupled with lifestyle modification support

    Other: Intervention Group

Interventions

  • OtherIntervention Group

    Short term comprehensive PCOS education coupled with lifestyle modification support

06

What researchers measure

Primary outcomes

  1. Difference in Modified PCOS Health-related Quality of life questionnaire (mPCOSQ) scoring between participants.

    Change in Polycystic ovarian Syndrome (PCOS) health-related quality of life assessed via the Modified PCOS Health-Related Quality of Life questionnaire (mPCOSQ) at two months and four months from baseline among intervention arm participants compared to controls. Scale Range: The instrument uses a 7-point scale, where lower scores (e.g., 1) represent a high negative impact on quality of life, and higher scores (e.g., 7) represent better quality of life.

    Time frame: 4 months

Secondary outcomes

  1. Change in body composition analysis

    Change in body composition analysis via seca mBCA (medical Body Composition Analyzer) at four months from baseline among intervention arm participants compared to controls.

    Time frame: 4 months

  2. Change in visceral adiposity index (VAI)

    Change in visceral adiposity index (VAI) via at four months from baseline among intervention arm participants compared to controls. A reliable indicator of visceral fat function associated with cardiometabolic risk. Sex-specific index, based on waist circumference, BMI, triglycerides, and HDL cholesterol, indirectly expressing visceral fat function.

    Time frame: 4 months

  3. Change in fasting glucose, fasting insulin, c-reactive protein (CRP) at four months from baseline among intervention arm participants compared to controls.

    Change in fasting glucose, fasting insulin, c-reactive protein (CRP) at four months from baseline among intervention arm participants compared to controls. Fasting glucose units - mg/dL Fasting insulin units - mU/mL C-reactive protein - mg/L

    Time frame: 4 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 11 months is below that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 6, 2026
StartActual
Jun 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07571915
Collaborators
American Academy of Family Physicians
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Jun 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion